Dactinomycin

證據等級: L5

預測適應症: 9 個

Dactinomycin: From Rhabdomyosarcoma / Wilms Tumor to Relapsing-Remitting Multiple Sclerosis

One-Sentence Summary

Dactinomycin (Actinomycin D) is a cytotoxic antibiotic and the cornerstone agent of the VAC regimen (vincristine + actinomycin D + cyclophosphamide), established in pediatric oncology for Wilms tumor, rhabdomyosarcoma, and gestational trophoblastic neoplasia — none of which are currently registered in the Philippines. The TxGNN model assigns its highest score to Relapsing-Remitting Multiple Sclerosis (RRMS) at 99.58%; however, no clinical trials and no publications currently support this application, and the mechanistic rationale is considered fundamentally incompatible with the safety requirements for RRMS management. Among all 9 predicted indications generated by this run, rhabdomyosarcoma subtypes — particularly parameningeal embryonal RMS (rank 5, L2 evidence, Phase 3 RCT data) — represent the most clinically actionable targets and merit prioritized review.

Quick Overview

Item	Content
Original Indication	Rhabdomyosarcoma, Wilms Tumor, Gestational Trophoblastic Neoplasia (globally established; not registered in the Philippines)
Predicted New Indication (Rank 1)	Relapsing-Remitting Multiple Sclerosis
TxGNN Prediction Score	99.58%
Evidence Level	L5
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data was not retrievable in the current evidence pack. Based on established pharmacology, dactinomycin intercalates into the minor groove of double-stranded DNA at guanine-cytosine-rich sequences, physically blocking the translocation of RNA polymerase and thereby inhibiting transcription globally. This mechanism distinguishes it from most modern oncology agents: rather than targeting a specific mutated pathway, it suppresses RNA synthesis in all rapidly proliferating cells. It was the first antibiotic demonstrated to have antineoplastic activity in humans and remains in clinical use for select rare pediatric malignancies.

The theoretical connection to RRMS rests on immunosuppression: by blocking transcription in activated lymphocytes, dactinomycin could in principle dampen cytokine production and curtail the autoimmune cascade driving demyelination. Precedent exists for this logic — cyclophosphamide and mitoxantrone, both cytotoxic agents, have been used in treatment-refractory MS, and the evidence pack’s mechanistic note (rank 1) itself acknowledges that dactinomycin theoretically carries immunosuppressive effects.

However, the argument collapses at the safety level. Dactinomycin carries a high risk of myelosuppression, potentially fatal hepatotoxicity including veno-occlusive disease (VOD), severe mucositis, and cumulative organ damage — all disqualifying for use in a chronic relapsing disease where patients are treated for decades. RRMS today has numerous highly effective and well-tolerated disease-modifying therapies (ocrelizumab, natalizumab, cladribine, siponimod), rendering dactinomycin’s risk-benefit ratio entirely untenable. The TxGNN’s high score almost certainly reflects graph-level topological proximity between “transcription inhibition” and “immune modulation” nodes rather than any direct clinical rationale. The current recommendation is Hold.

Clinical Trial Evidence

Currently no related clinical trials registered for dactinomycin in relapsing-remitting multiple sclerosis.

Literature Evidence

Currently no related literature available for dactinomycin in relapsing-remitting multiple sclerosis.

Philippines Market Information

Dactinomycin is not registered or marketed in the Philippines. There are currently 0 active licenses on record with the Philippine FDA. Any potential clinical use would require importation approval and a special compassionate use or expanded access permit under Philippine FDA regulations.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — DNA intercalating antibiotic (actinomycin class); not a targeted therapy or immunotherapy
Myelosuppression Risk	High — dose-dependent suppression of all hematopoietic cell lines; neutropenia, thrombocytopenia, and anemia are commonly reported in pediatric oncology series; nadir typically 14–21 days post-dose
Emetogenicity Classification	Moderate
Monitoring Items	CBC with differential (weekly during active treatment), liver function tests (ALT, AST, total bilirubin, alkaline phosphatase), renal function, weight and fluid balance (veno-occlusive disease surveillance), and platelet trends
Handling Protection	Must follow full cytotoxic drug handling regulations; intravenous administration only (no oral form); closed-system transfer devices and dedicated chemotherapy PPE required

Safety Considerations

Formal package insert warnings and contraindications are not available in this evidence pack and should be retrieved from the manufacturer or the Philippine FDA prior to any clinical review. Based on the literature identified during evidence collection, the following safety signals are documented:

Hepatotoxicity / Veno-Occlusive Disease (VOD): Multiple independent reports link dactinomycin-containing VAC regimens to hepatic VOD, including fatalities; risk is significantly higher in children under 3 years of age (PMIDs 9191535, 7700188, 11378345, 15143082)
Age-related hepatopathy: Age is an independent risk factor for VAC-induced hepatopathy; young children require closer liver function monitoring (PMID 15143082)
Cumulative myelosuppression: Dose-dependent suppression with potential for treatment-limiting cytopenias; dosing guidance based on evidence has historically been limited (PMID 21671362)

Conclusion and Next Steps

Decision: Hold (for RRMS — Rank 1 TxGNN prediction)

Rationale: There is no clinical evidence and no mechanistically plausible basis to support dactinomycin in RRMS; its extreme toxicity profile is incompatible with a chronic autoimmune disease setting where effective low-toxicity alternatives already exist. The high TxGNN score reflects knowledge graph topology, not clinical viability.

To proceed with meaningful drug repurposing evaluation, the following is needed:

Redirect primary analysis to better-evidenced RMS-related indications (see summary table below)
Retrieve MOA data from the DrugBank API (data gap DG002) to enable formal mechanism-of-action linkage analysis
Obtain TFDA/Philippine FDA package insert PDF to address the blocking safety data gap (DG001) before any indication can advance to Stage 1 safety screening
For parameningeal embryonal RMS specifically, obtain current COG/EpSSG protocol versions to confirm dactinomycin’s current role in standard-of-care

Summary of All 9 Predicted Indications

The following table captures the full TxGNN output landscape for reference. The RRMS prediction (rank 1) is evaluated in detail above.

Rank	Indication	TxGNN Score	Evidence Level	Decision
1	Relapsing-Remitting Multiple Sclerosis	99.58%	L5	Hold
2	Botryoid-Type Embryonal RMS of the Vagina	99.54%	L4	Research Question
3	Extrahepatic Bile Duct Rhabdomyosarcoma	99.49%	L4	Research Question
4	Embryonal Extrahepatic Bile Duct RMS	99.48%	L5	Hold (merge with Rank 3)
5	Parameningeal Embryonal RMS	99.48%	L2	Proceed with Guardrails
6	Prostate Embryonal RMS	99.46%	L3	Research Question
7	Liver Sarcoma	99.42%	L3	Research Question
8	Upper Aerodigestive Tract Neoplasm	99.16%	L3	Research Question
9	Head and Neck Cancer	99.16%	L3	Research Question

Parameningeal embryonal RMS (rank 5) is the most immediately actionable candidate: IRS-IV Phase 3 RCT data (PMID 19770373, n > 800) directly establishes dactinomycin as a core component of the standard-of-care VAC regimen for this high-risk subtype, and IRS-III outcomes analysis (PMID 10856103) further supports intensified VAC for local/regional embryonal RMS. A dedicated evidence report for this indication is recommended as the next step.

⚠️ This report is generated for research reference only and does not constitute medical advice. All drug repurposing candidates require formal clinical validation before application. This document contains YMYL-sensitive content; consult qualified medical professionals for clinical decisions.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.